No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
Aier Eye Hospital Group Co., Ltd. is a prominent provider of ophthalmic healthcare services and institutions. Its comprehensive medical offerings encompass specialties such as the diagnosis and treatment of fundus diseases, optometry, refractive correction, glaucoma, corneal conditions, and cataracts. Beyond direct patient care, the company also conducts training courses focused on cataract prevention and management. The group boasts an extensive international footprint, operating approximately 500 ophthalmic facilities across mainland China, with additional presences including 86 in Europe, 1 in the United States, 7 in Hong Kong, and 12 throughout Southeast Asia. Founded in 2007, Aier Eye Hospital Group maintains its headquarters in Changsha, China.
www.aierchina.comNo one on the platform currently holds 300015.SZ.
No tracked institution reports a position in 300015.SZ as of their last filing.
No one on the platform has traded 300015.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.7% | 19.9% | 20.4% | — | — | — |
| Rev. Growth % | 6.5% | 13.4% | ||||
| Profit Margin % | 14.5% | 15.8% | 14.6% | |||
| Free Cash Flow Margin % | 17.4% | 18.0% | 15.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $23.8B | +5.7% | $0.32 | $0.31–$0.34 | — | 6 |
| 2027 | $25.8B | +8.5% | $0.43 | $0.43–$0.44 | — | 9 |
| 2028 | $28.2B | +9.3% | $0.49 | $0.44–$0.52 | — | 13 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | $0.07 | $0.02 | -70.7% |
| 2026-04-24 | $0.13 | $0.13 | +0.0% |
| 2026-04-23 | $0.04 | $0.01 | -77.8% |
| 2025-10-27 | $0.14 | $0.12 | -20.3% |
| 2025-08-27 | $0.12 | $0.11 | -8.2% |
| 2025-04-24 | $0.04 | $0.01 | -75.0% |
| 2024-10-31 | $0.15 | $0.15 | +0.0% |
| $26.75 |
| -0.63% |
| $82.2B |
| — |
| 300832.SZShenzhen New Industries Biomedical Engineering Co., Ltd. | $48.95 | +0.84% | $38.5B | — |
| 600196.SSShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $21.81 | -0.64% | $57.6B | — |
Source: Financial Modeling Prep · peers by sector/industry